DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the i...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Izabella Liguori Corsino VABO [verfasserIn] Lincoln Eduardo Villela Vieira de Castro FERREIRA [verfasserIn] Fábio Heleno Lima PACE [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Arquivos de Gastroenterologia - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 |
|---|
| Links: |
|---|
| DOI / URN: |
10.1590/S0004-28032016000100005 |
|---|
| Katalog-ID: |
DOAJ073518786 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ073518786 | ||
| 003 | DE-627 | ||
| 005 | 20230309115436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228nuuuuuuuuxx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/S0004-28032016000100005 |2 doi | |
| 035 | |a (DE-627)DOAJ073518786 | ||
| 035 | |a (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC799-869 | |
| 100 | 0 | |a Izabella Liguori Corsino VABO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. | ||
| 650 | 4 | |a Depressão | |
| 650 | 4 | |a Hepatite C crônica | |
| 650 | 4 | |a Interferon-alfa | |
| 653 | 0 | |a Diseases of the digestive system. Gastroenterology | |
| 700 | 0 | |a Lincoln Eduardo Villela Vieira de Castro FERREIRA |e verfasserin |4 aut | |
| 700 | 0 | |a Fábio Heleno Lima PACE |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Arquivos de Gastroenterologia |d Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 |w (DE-627)503329355 |w (DE-600)2210583-9 |x 16784219 |7 nnns |
| 856 | 4 | 0 | |u https://doi.org/10.1590/S0004-28032016000100005 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1678-4219 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| author_variant |
i l c v ilcv l e v v d c f levvdcf f h l p fhlp |
|---|---|
| matchkey_str |
article:16784219:uuuuuuuu::ersiepsdicdnenainsihhoihpttstetdihey |
| callnumber-subject-code |
RC |
| allfields |
10.1590/S0004-28032016000100005 doi (DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 DE-627 ger DE-627 rakwb eng RC799-869 Izabella Liguori Corsino VABO verfasserin aut DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology Lincoln Eduardo Villela Vieira de Castro FERREIRA verfasserin aut Fábio Heleno Lima PACE verfasserin aut In Arquivos de Gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 (DE-627)503329355 (DE-600)2210583-9 16784219 nnns https://doi.org/10.1590/S0004-28032016000100005 kostenfrei https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en kostenfrei https://doaj.org/toc/1678-4219 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| spelling |
10.1590/S0004-28032016000100005 doi (DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 DE-627 ger DE-627 rakwb eng RC799-869 Izabella Liguori Corsino VABO verfasserin aut DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology Lincoln Eduardo Villela Vieira de Castro FERREIRA verfasserin aut Fábio Heleno Lima PACE verfasserin aut In Arquivos de Gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 (DE-627)503329355 (DE-600)2210583-9 16784219 nnns https://doi.org/10.1590/S0004-28032016000100005 kostenfrei https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en kostenfrei https://doaj.org/toc/1678-4219 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfields_unstemmed |
10.1590/S0004-28032016000100005 doi (DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 DE-627 ger DE-627 rakwb eng RC799-869 Izabella Liguori Corsino VABO verfasserin aut DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology Lincoln Eduardo Villela Vieira de Castro FERREIRA verfasserin aut Fábio Heleno Lima PACE verfasserin aut In Arquivos de Gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 (DE-627)503329355 (DE-600)2210583-9 16784219 nnns https://doi.org/10.1590/S0004-28032016000100005 kostenfrei https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en kostenfrei https://doaj.org/toc/1678-4219 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsGer |
10.1590/S0004-28032016000100005 doi (DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 DE-627 ger DE-627 rakwb eng RC799-869 Izabella Liguori Corsino VABO verfasserin aut DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology Lincoln Eduardo Villela Vieira de Castro FERREIRA verfasserin aut Fábio Heleno Lima PACE verfasserin aut In Arquivos de Gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 (DE-627)503329355 (DE-600)2210583-9 16784219 nnns https://doi.org/10.1590/S0004-28032016000100005 kostenfrei https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en kostenfrei https://doaj.org/toc/1678-4219 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| allfieldsSound |
10.1590/S0004-28032016000100005 doi (DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 DE-627 ger DE-627 rakwb eng RC799-869 Izabella Liguori Corsino VABO verfasserin aut DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology Lincoln Eduardo Villela Vieira de Castro FERREIRA verfasserin aut Fábio Heleno Lima PACE verfasserin aut In Arquivos de Gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004 (DE-627)503329355 (DE-600)2210583-9 16784219 nnns https://doi.org/10.1590/S0004-28032016000100005 kostenfrei https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en kostenfrei https://doaj.org/toc/1678-4219 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR |
| language |
English |
| source |
In Arquivos de Gastroenterologia |
| sourceStr |
In Arquivos de Gastroenterologia |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Depressão Hepatite C crônica Interferon-alfa Diseases of the digestive system. Gastroenterology |
| isfreeaccess_bool |
true |
| container_title |
Arquivos de Gastroenterologia |
| authorswithroles_txt_mv |
Izabella Liguori Corsino VABO @@aut@@ Lincoln Eduardo Villela Vieira de Castro FERREIRA @@aut@@ Fábio Heleno Lima PACE @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| hierarchy_top_id |
503329355 |
| id |
DOAJ073518786 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073518786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115436.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0004-28032016000100005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073518786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC799-869</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Izabella Liguori Corsino VABO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Depressão</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatite C crônica</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon-alfa</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the digestive system. Gastroenterology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lincoln Eduardo Villela Vieira de Castro FERREIRA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fábio Heleno Lima PACE</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arquivos de Gastroenterologia</subfield><subfield code="d">Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004</subfield><subfield code="w">(DE-627)503329355</subfield><subfield code="w">(DE-600)2210583-9</subfield><subfield code="x">16784219</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0004-28032016000100005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1678-4219</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Izabella Liguori Corsino VABO |
| spellingShingle |
Izabella Liguori Corsino VABO misc RC799-869 misc Depressão misc Hepatite C crônica misc Interferon-alfa misc Diseases of the digestive system. Gastroenterology DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| authorStr |
Izabella Liguori Corsino VABO |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)503329355 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC799-869 |
| illustrated |
Not Illustrated |
| issn |
16784219 |
| topic_title |
RC799-869 DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN Depressão Hepatite C crônica Interferon-alfa |
| topic |
misc RC799-869 misc Depressão misc Hepatite C crônica misc Interferon-alfa misc Diseases of the digestive system. Gastroenterology |
| topic_unstemmed |
misc RC799-869 misc Depressão misc Hepatite C crônica misc Interferon-alfa misc Diseases of the digestive system. Gastroenterology |
| topic_browse |
misc RC799-869 misc Depressão misc Hepatite C crônica misc Interferon-alfa misc Diseases of the digestive system. Gastroenterology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Arquivos de Gastroenterologia |
| hierarchy_parent_id |
503329355 |
| hierarchy_top_title |
Arquivos de Gastroenterologia |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)503329355 (DE-600)2210583-9 |
| title |
DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| ctrlnum |
(DE-627)DOAJ073518786 (DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25 |
| title_full |
DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| author_sort |
Izabella Liguori Corsino VABO |
| journal |
Arquivos de Gastroenterologia |
| journalStr |
Arquivos de Gastroenterologia |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| contenttype_str_mv |
txt |
| author_browse |
Izabella Liguori Corsino VABO Lincoln Eduardo Villela Vieira de Castro FERREIRA Fábio Heleno Lima PACE |
| class |
RC799-869 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Izabella Liguori Corsino VABO |
| doi_str_mv |
10.1590/S0004-28032016000100005 |
| author2-role |
verfasserin |
| title_sort |
depressive episode incidence in patients with chronic hepatitis c treated with pegylated interferon and ribavirin |
| callnumber |
RC799-869 |
| title_auth |
DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| abstract |
ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. |
| abstractGer |
ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. |
| abstract_unstemmed |
ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN |
| url |
https://doi.org/10.1590/S0004-28032016000100005 https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en https://doaj.org/toc/1678-4219 |
| remote_bool |
true |
| author2 |
Lincoln Eduardo Villela Vieira de Castro FERREIRA Fábio Heleno Lima PACE |
| author2Str |
Lincoln Eduardo Villela Vieira de Castro FERREIRA Fábio Heleno Lima PACE |
| ppnlink |
503329355 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1590/S0004-28032016000100005 |
| callnumber-a |
RC799-869 |
| up_date |
2024-07-03T18:08:19.771Z |
| _version_ |
1803582281901670401 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073518786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309115436.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0004-28032016000100005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073518786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7022bdbb9cd44cecadeeae51bd4b9d25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC799-869</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Izabella Liguori Corsino VABO</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT Background The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity Objective Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode. Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients ( P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P =0.66). Conclusion The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Depressão</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatite C crônica</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon-alfa</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the digestive system. Gastroenterology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lincoln Eduardo Villela Vieira de Castro FERREIRA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fábio Heleno Lima PACE</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arquivos de Gastroenterologia</subfield><subfield code="d">Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2004</subfield><subfield code="w">(DE-627)503329355</subfield><subfield code="w">(DE-600)2210583-9</subfield><subfield code="x">16784219</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0004-28032016000100005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7022bdbb9cd44cecadeeae51bd4b9d25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032016000100020&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1678-4219</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| score |
7.3995867 |